Compare Abbott Laboratories (ABT) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $107.57. The key difference: Abbott Laboratories pays a 2.63% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABT | LQD | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | — |
52-Week High | $136.62 | $112.91 |
52-Week Low | $82.57 | $107.12 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, is trading at $108.67, showing minimal daily change. The technical outlook is bearish based on moving averages, though short-term oscillators like the RSI suggest potential oversold conditions. Recent news highlights strong investor flows into bond ETFs amid market uncertainty and rate hike speculation, positioning LQD as a core vehicle for investment-grade corporate bond exposure.
The outlook for LQD is tied to interest rate expectations and corporate credit health. The primary opportunity lies in its role as a liquid, diversified source of investment-grade yield, especially if rate hikes pause. Key risks include rising interest rates pressuring bond prices and potential credit spread widening if economic conditions deteriorate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
